Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target

PLoS One. 2013 Jul 19;8(7):e69354. doi: 10.1371/journal.pone.0069354. Print 2013.

Abstract

In previous research, we found α-enolase to be inversely correlated with progression-free and overall survival in lung cancer patients and detected α-enolase on the surface of lung cancer cells. Based on these findings, we hypothesized that surface α-enolase has a significant role in cancer metastasis and tested this hypothesis in the current study. We found that α-enolase was co-immunoprecipitated with urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen in lung cancer cells and interacted with these proteins in a cell-free dot blotting assay, which can be interrupted by α-enolase-specific antibody. α-Enolase in lung cancer cells co-localized with these proteins and was present at the site of pericellular degradation of extracellular matrix components. Treatment with antibody against α-enolase in vitro suppressed cell-associated plasminogen and matrix metalloproteinase activation, collagen and gelatin degradation, and cell invasion. Examination of the effect of treatment with shRNA plasmids revealed that down regulation of α-enolase decreases extracellular matrix degradation by and the invasion capacity of lung cancer cells. Adoptive transfer of α-enolase-specific antibody to mice resulted in accumulation of antibody in subcutaneous tumor and inhibited the formation of tumor metastasis in lung and bone. This study demonstrated that surface α-enolase promotes extracellular matrix degradation and invasion of cancer cells and that targeting surface α-enolase is a promising approach to suppress tumor metastasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacology
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / metabolism
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Cell Line, Tumor
  • Cell Membrane / metabolism*
  • Cell Movement
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / metabolism
  • Extracellular Matrix / metabolism*
  • Humans
  • Immunocompromised Host
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Male
  • Mice
  • Neoplasm Metastasis
  • Neoplasms / metabolism*
  • Neoplasms / mortality
  • Neoplasms / pathology*
  • Phosphopyruvate Hydratase / antagonists & inhibitors
  • Phosphopyruvate Hydratase / metabolism*
  • Plasminogen / metabolism
  • Protein Binding
  • Receptors, Urokinase Plasminogen Activator / metabolism
  • Tumor Suppressor Proteins / antagonists & inhibitors
  • Tumor Suppressor Proteins / metabolism
  • Urokinase-Type Plasminogen Activator / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Receptors, Urokinase Plasminogen Activator
  • Tumor Suppressor Proteins
  • Plasminogen
  • Urokinase-Type Plasminogen Activator
  • ENO1 protein, human
  • Phosphopyruvate Hydratase

Grants and funding

This work was supported by grants from the Department of Health, Taiwan, to G.-C. Chang (China Medical University Hospital Cancer Research Center of Excellence, DOH100-TD-C-111-005), N.-Y. Shih (DOH99-TD-G-111-009), and C.-C. Kuo (DOH100-TD-C-111-004) and grants from the National Science Council, Taiwan, to K.-J. Liu (NSC98-3112-B-400-012, 99-3112-B-400-004, and 100-3112-B-400-014), and C.-C. Kuo (NSC98-2320-B-400-003-MY3). G.-C. Chang was supported by a VGHTC grant (TCVGH-963205C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.